Insights

Loading spinner
Gathering insights about Invivyd

Invivyd Tech Stack

Invivyd uses 8 technology products and services including SQL, oEmbed, Microsoft Excel, and more. Explore Invivyd's tech stack below.

  • SQL
    Database
  • oEmbed
    Dev Tools
  • Microsoft Excel
    Editors
  • Sophos
    Email Security
  • Font Awesome
    Font Scripts
  • SAML
    Identity And Access Management
  • macOS
    Operating Systems & Computing Languages
  • WP Engine
    Platform As A Service

Media & News

Invivyd's Email Address Formats

Invivyd uses at least 2 format(s):
Invivyd Email FormatsExamplePercentage
First.Last@adagiotx.comJohn.Doe@adagiotx.com
65%
FLast@adagiotx.comJDoe@adagiotx.com
20%
FirstLast@adagiotx.comJohnDoe@adagiotx.com
14%
FirstLas@adagiotx.comJohnDoe@adagiotx.com
1%
FLast@invivyd.comJDoe@invivyd.com
95%
First.Last@invivyd.comJohn.Doe@invivyd.com
5%

Frequently Asked Questions

What is Invivyd's stock symbol?

Minus sign iconPlus sign icon
Invivyd is a publicly traded company; the company's stock symbol is IVVD.

What is Invivyd's official website and social media links?

Minus sign iconPlus sign icon
Invivyd's official website is invivyd.com and has social profiles on LinkedInCrunchbase.

What is Invivyd's SIC code NAICS code?

Minus sign iconPlus sign icon
Invivyd's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Invivyd have currently?

Minus sign iconPlus sign icon
As of December 2025, Invivyd has approximately 114 employees across 1 continents, including North America. Key team members include Chief Human Resources Officer: J. G.Chief Scientific Officer: R. A.Chief Financial Officer: W. D.. Explore Invivyd's employee directory with LeadIQ.

What industry does Invivyd belong to?

Minus sign iconPlus sign icon
Invivyd operates in the Biotechnology Research industry.

What technology does Invivyd use?

Minus sign iconPlus sign icon
Invivyd's tech stack includes SQLoEmbedMicrosoft ExcelSophosFont AwesomeSAMLmacOSWP Engine.

What is Invivyd's email format?

Minus sign iconPlus sign icon
Invivyd's email format typically follows the pattern of First.Last@adagiotx.com. Find more Invivyd email formats with LeadIQ.

How much funding has Invivyd raised to date?

Minus sign iconPlus sign icon
As of December 2025, Invivyd has raised $58M in funding. The last funding round occurred on Aug 20, 2025 for $58M.

When was Invivyd founded?

Minus sign iconPlus sign icon
Invivyd was founded in 2020.

Invivyd

Biotechnology ResearchConnecticut, United States51-200 Employees

Invivyd, Inc. (Nasdaq: IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies.

In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
#covid19 #immunocompromised

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
IVVD
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
51-200

Section iconFunding & Financials

  • $58M

    Invivyd has raised a total of $58M of funding over 5 rounds. Their latest funding round was raised on Aug 20, 2025 in the amount of $58M.

  • $50M$100M

    Invivyd's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $58M

    Invivyd has raised a total of $58M of funding over 5 rounds. Their latest funding round was raised on Aug 20, 2025 in the amount of $58M.

  • $50M$100M

    Invivyd's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.